Advanced searches left 3/3

Leukaemia - Crossref

Summarized by Plex Scholar
Last Updated: 27 July 2022

* If you want to update the article please login/register

Optimising care for UK patients with acute myeloid leukaemia

Astellas Pharma Ltd contributed and funded this article. Astellas Pharma Ltd also contributed editorially in the creation of this article. Source of coverage: June 2022 Acute myeloid leukaemia is a rare disease in the United Kingdom, with approximately 3000 cases diagnosed each year. Transplantation technology advancements have increased donor availability and reduced transplant toxicity, which have both improved transplant availability and reduced transplant toxicity. Patients with acute myeloid leukaemia have been aided in their recovery by improved knowledge of the cytogenetics and molecular genetics of acute myeloid leukaemia, at the same time, increasing knowledge of acute myeloid leukaemia has increased the likelihood of surviving patients.

Source link: https://doi.org/10.12968/hmed.2022.0229


PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia

Abstract: Abstract Mould-active antifungal prophylaxis is often used to prevent invasive fungal disease in patients with acute leukaemia treated with intensive chemotherapy. Antifungal drugs have important interactions, can cause severe adverse events, and can promote antifungal resistance formation. Both screening for infection in patients not on prophylaxis and ruling out infection in patients treated empirically suggest that regular biomarkers could be used safely as part of an antifungal stewardship program to reduce antifungal use.

Source link: https://doi.org/10.1093/jacamr/dlac074


Cytotoxic Activity of Aquilaria malaccensis Ethanolic Leaves Extract on Human Chronic Myeloid Leukaemia K-562 Cell Line

The aim of this research was to determine the cytotoxic effects of an ethanolic extract of A. malaccensis on the human chronic myeloid leukaemia K-562 cell line. Using assay was found in this study, cytotoxic properties of an ethanolic extract of A. malaccensis leaves on K-562 cells. At 72 hours of incubation, the half-maximal inhibitory concentration of A. malaccensis leaves was noted; 90 g/mL for 70% ethanolic extract; 86 g/mL for 70% ethanolic extract. The ethanolic extract of A. malaccensis leaves converted K-562 cells into apoptotic cell death mode, according to the study.

Source link: https://doi.org/10.37231/ajmb.2022.6.1.449


Mathematical models of leukaemia and its treatment: a review

Abstract Leukaemia accounts for around 3% of all cancer types diagnosed in adults, and it is the most common form of cancer in children under paediatric age. While showing a complementary picture to experimental biomedical studies, there is growing curiosity in the use of mathematical models in oncology to draw inferences and make predictions.

Source link: https://doi.org/10.1007/s40324-022-00296-z


Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis

About 2. 8 percent of all new cancer incidence and 36 percent of cancer-related deaths, according to Leukaemia. To determine the age-standardised prevalence of lifestyle and metabolic risk factors, we used the WHO Global Health Observatory data repository. The incidence and mortality of leukaemia were correlated with Human Development Index, Gross Domestic Products per capita, incidence of smoking, physical fitness, overweight, obesity, and hypercholesterolaemia at the national level. However, an increasing trend of leukaemia was found in Germany, Korea, Japan, Canada, and the United Kingdom, although its deaths in the Philippines, Ecuador, Belarus, and Thailand increased. In some populations, there was a decreasing trend of leukaemia for the past decade, but an increase in incidence and mortality was observed in some countries. In regions with these trends, more radical lifestyle changes should be introduced to combat the growing trend of leukaemia in regions with those trends.

Source link: https://doi.org/10.3389/fonc.2022.904292


CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy

Abstract Primary antifungal chemoprophylaxis is the most common treatment of choice for the prevention of invasive fungal disease in patients with acute leukaemia. Galactomannan and 1,3-d-glucan have been listed as an alternative pact to PAC for these patients by twice-weekly monitoring. Drug interactions and antifungal resistance are also discussed in this report.

Source link: https://doi.org/10.1093/jacamr/dlac081


Causative Pathogens of Febrile Neutropaenia in Children Treated for Acute Lymphoblastic Leukaemia

Introduction: The therapy of acute lymphoblastic leukaemia using intensive chemotherapy has resulted in high cure rates but also significant morbidity. In a cohort of children treated for ALL at our hospital, the aim of this research was to describe the microbiological aetiology and clinical outcomes of episodes of chemotherapy-induced febrile neutropaenia in a cohort of children. Patients with ALL were treated with either the HKSGALL93 or the Malaysia-Singapore 2003 chemotherapy protocols. The records of 197 patients who underwent the intensive phase of therapy, defined as the period of induction, central nervous system-directed therapy, and reinduction from June 2000 to January 2010, were retrospectively reviewed. Results: In 197 patients, there were 587 episodes of febrile neutropaenia, resulting in a total rate of 2. 98 episodes per patient.

Source link: https://doi.org/10.47102/annals-acadmedsg.v44n11p530


Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study

Abstract Aims Patients with persistent myeloid leukaemia have a higher risk of cardiovascular events than imatinib in patients with a second generation breakpoint cluster region. Hence, this research was designed to investigate the association between cardiovascular events and TKIs in patients with CML. Methods and findings This retrospective population-based cohort study enrolled first-time users of imatinib, dasatinib, and nilotinib between 1 January 2007 and December 16, 2016. Also, the competing risk was adjusted using the Fine and Gray competing risk model. Nilotinib had a significantly higher ATE risk than imatinib, and imatinib had a higher risk of ATE exposure than imatinib. The risks of ATE and other cardiovascular-related activities were similar between dasatinib and imatinib, as well as between nilotinib and dasatinib, as well as between nilotinib and dasatinib. Conclusions Patients treated with Nilotinib had a significantly higher risk of experiencing ATE than those treated with imatinib. However, the risks of ATE and other cardiovascular-related events were not significantly different between dasatinib and imatinib.

Source link: https://doi.org/10.1093/eurjpc/zwab043

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions